Montreal – November 11 2020 – CQDM congratulates Mesentech on securing additional investment to support the clinical development of their bone-targeting drug candidate MES-1007, a drug with the potential to reverse bone wastage in Duchenne Muscular Dystrophy and other skeletal fragility diseases in pediatrics.
Link to Mesentech’s Press Release: click here.
“CQDM’s investment enabled Mesentech to generate the safety data that validated our technology’s ability to mitigate side effects that precluded previous drug-development efforts in this drug class. This was key data that our new partners required to support a clinical program for DMD,” said Jonathan Polak, Mesentech’s CEO.
“CQDM is proud of the impact that our investment has already had and is excited by the progress that Mesentech has made in advancing MES-1007 towards the clinic”, said Jesse Paterson, CQDM’S Senior Director, Business Development. “The investment by patient foundations such as CureDuchenne and the Charles H. Hood Foundation (CHF) speaks to the tremendous potential for MES-1007 as a bone targeted therapy,” added Jesse Paterson.
CQDM is a biopharma-based research consortium created in 2008 with the mission to fund the development of innovative technologies to accelerate the discovery and development of drugs and vaccines. Its business model is based on a collaborative approach bringing together world-leading pharmaceutical organizations, Canadian biotech companies as well as the Canadian and Quebec governments who share the costs of the research. CQDM uses this leverage to reduce the risks inherent to early-stage biopharmaceutical research. In doing so, CQDM bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned. CQDM receives contributions from Quebec’s Ministry of Economy and Innovation (MEI), from large pharmaceutical companies, and from the Government of Canada under the Business-Led Networks of Centres of Excellence Program (BL-NCE). For more information: https://cqdm.org/en
Mesentech is a Vancouver-based biotechnology company dedicated to developing platform technologies to treat diseases and conditions of bones. Dr. Robert Young, founder of Mesentech, spearheaded the discovery of life-changing therapeutics such as Singulair® and Arcoxia® while leading medicinal chemistry at the Merck Frosst Centre for Therapeutic Research in Montreal.